| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
88,803 |
81,467 |
$8.58M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
55,698 |
52,267 |
$3.81M |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
34,993 |
33,082 |
$1.36M |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
30,599 |
29,419 |
$1.30M |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
10,874 |
10,527 |
$1.21M |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
11,455 |
11,211 |
$1.17M |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
10,651 |
10,412 |
$1.09M |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
10,407 |
9,426 |
$944K |
| 99215 |
Prolong outpt/office vis |
4,825 |
4,473 |
$621K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
34,322 |
18,747 |
$598K |
| 99051 |
|
27,334 |
26,079 |
$570K |
| 99401 |
|
24,125 |
21,806 |
$442K |
| 96127 |
|
61,931 |
56,571 |
$441K |
| 99188 |
|
24,701 |
24,102 |
$441K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
27,621 |
26,640 |
$425K |
| 99429 |
|
27,242 |
18,464 |
$407K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
7,303 |
7,138 |
$303K |
| Q3014 |
Telehealth originating site facility fee |
9,497 |
8,790 |
$186K |
| 96160 |
|
18,559 |
17,482 |
$180K |
| G0447 |
Face-to-face behavioral counseling for obesity, 15 minutes |
45,742 |
43,914 |
$157K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
9,507 |
9,055 |
$116K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,037 |
1,985 |
$108K |
| 97802 |
|
16,068 |
15,562 |
$79K |
| 80061 |
Lipid panel |
4,158 |
3,863 |
$70K |
| 87077 |
|
12,313 |
11,680 |
$64K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
4,964 |
3,768 |
$56K |
| 92552 |
|
3,262 |
3,232 |
$49K |
| 99050 |
|
1,672 |
1,592 |
$40K |
| 99460 |
|
339 |
306 |
$29K |
| 94760 |
|
3,704 |
3,510 |
$28K |
| G9920 |
Screening performed and negative |
8,499 |
7,923 |
$25K |
| 99238 |
Hospital discharge day management, 30 minutes or less |
324 |
298 |
$21K |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
5,378 |
5,082 |
$21K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,091 |
1,038 |
$21K |
| 87807 |
|
1,294 |
1,256 |
$20K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
1,923 |
1,785 |
$19K |
| 81002 |
|
5,462 |
5,102 |
$18K |
| 0002A |
|
414 |
409 |
$17K |
| 0001A |
|
350 |
347 |
$14K |
| 96161 |
|
3,742 |
3,361 |
$13K |
| 87088 |
|
2,527 |
2,093 |
$11K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
101 |
91 |
$10K |
| 0072A |
|
249 |
224 |
$10K |
| 0071A |
|
244 |
212 |
$10K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
93 |
93 |
$7K |
| 83655 |
|
706 |
657 |
$7K |
| 86756 |
|
453 |
431 |
$6K |
| 36415 |
Collection of venous blood by venipuncture |
7,977 |
7,456 |
$5K |
| 82947 |
|
1,068 |
988 |
$5K |
| 0054A |
|
117 |
115 |
$5K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
372 |
367 |
$4K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
244 |
235 |
$4K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
77 |
77 |
$4K |
| 99354 |
|
71 |
55 |
$4K |
| 90651 |
|
2,442 |
2,363 |
$4K |
| 82948 |
|
568 |
553 |
$2K |
| 82465 |
|
602 |
575 |
$2K |
| 86308 |
|
332 |
317 |
$2K |
| 85018 |
|
707 |
695 |
$2K |
| 90677 |
|
519 |
426 |
$2K |
| 0004A |
|
31 |
31 |
$1K |
| 95117 |
|
59 |
49 |
$1K |
| 0051A |
|
26 |
25 |
$953.60 |
| 90686 |
|
7,009 |
6,820 |
$854.08 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
371 |
348 |
$674.08 |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
549 |
506 |
$672.00 |
| 69210 |
|
12 |
12 |
$573.93 |
| 94010 |
|
14 |
14 |
$394.65 |
| 94761 |
|
13 |
12 |
$253.95 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
285 |
277 |
$200.79 |
| 99173 |
|
2,951 |
2,905 |
$177.79 |
| 90670 |
|
4,519 |
4,279 |
$175.44 |
| 2015F |
|
13 |
12 |
$140.00 |
| J7050 |
Infusion, normal saline solution, 250 cc |
230 |
219 |
$109.06 |
| 90633 |
|
1,207 |
1,165 |
$105.44 |
| 90672 |
|
13 |
13 |
$53.76 |
| 99072 |
|
4,886 |
4,567 |
$41.20 |
| 90620 |
|
1,258 |
1,180 |
$21.93 |
| 90656 |
|
402 |
398 |
$21.93 |
| 36416 |
|
388 |
372 |
$6.04 |
| J7611 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg |
93 |
90 |
$3.42 |
| 91300 |
|
62 |
59 |
$0.26 |
| 91307 |
|
479 |
394 |
$0.03 |
| 90723 |
|
2,998 |
2,791 |
$0.00 |
| 90647 |
|
28 |
28 |
$0.00 |
| 90696 |
|
26 |
25 |
$0.00 |
| 91305 |
|
177 |
169 |
$0.00 |
| 90648 |
|
3,044 |
2,849 |
$0.00 |
| 90681 |
|
559 |
520 |
$0.00 |
| 90734 |
|
1,932 |
1,840 |
$0.00 |
| 90710 |
|
964 |
935 |
$0.00 |
| 90715 |
|
152 |
146 |
$0.00 |
| 90685 |
|
51 |
50 |
$0.00 |